Li Yongze, Teng Di, Shi Xiaoguang, Teng Xiaochun, Teng Weiping, Shan Zhongyan, Lai Yaxin
Department of Endocrinology and Metabolism and the Institute of Endocrinology, First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
Lancet Reg Health West Pac. 2021 Jul 31;15:100227. doi: 10.1016/j.lanwpc.2021.100227. eCollection 2021 Oct.
Previous studies have shown increases in the prevalence of obesity and hypertension, but nationally representative data on recent changes in prevalence adjusted for population structure changes are lacking. Two nationwide surveys were conducted in 2007 and 2017 to assess the prevalence changes of these conditions in China.
A multistage stratified random sampling method was used to obtain a nationally representative sample of adults aged 20 years and older in mainland China in 2007 and 2017. Temporal changes in the prevalence of hypertension and obesity were investigated. Changes in blood pressure, body mass index (BMI) and waist circumference were also assessed. Logistic regression models were constructed to assess the changes in prevalence over time.
The weighted prevalence of hypertension (25.7% vs. 31.5%, =0.04), high-normal blood pressure (11.7% vs. 14.3%, <0.0001), general obesity (31.9% vs. 37.2%, =0.008), and central obesity (25.9% vs. 35.4%, =0.0002) was significantly higher in 2017 (n=72824) than in 2007 (n=45956) in the overall population. No significant changes in the prevalence of overweight and grade 1 or grade 2 hypertension were observed in the overall population, but a significantly higher prevalence was observed among participants aged 20-29 years for grade 1 hypertension (=0.002) and among participants aged 70 years and older for grade 2 hypertension (=0.046) in 2017.
Compared with 2007, the prevalence of hypertension and obesity was significantly higher among adults in mainland China after adjusting for demographic confounding factors in 2017. More targeted interventions and prevention strategies are needed to offset the increasing risk of cardiovascular disease due to increases in the prevalence of hypertension and obesity.
The Clinical Research Fund of the Chinese Medical Association (Grant No. 15010010589), the National Natural Science Foundation of China (Grant No. 82000753), and the Chinese Medical Association Foundation and Chinese Diabetes Society (Grant No. 07020470055).
既往研究显示肥胖和高血压患病率有所上升，但缺乏针对人口结构变化进行调整的近期患病率变化的全国代表性数据。2007年和2017年进行了两项全国性调查，以评估中国这些疾病的患病率变化。
采用多阶段分层随机抽样方法，获取2007年和2017年中国大陆20岁及以上成年人的全国代表性样本。调查高血压和肥胖患病率的时间变化。还评估了血压、体重指数（BMI）和腰围的变化。构建逻辑回归模型以评估患病率随时间的变化。
总体人群中，2017年（n = 72824）高血压加权患病率（25.7% 对 31.5%，P = 0.04）、高正常血压患病率（11.7% 对 14.3%，P < 0.0001）、一般肥胖患病率（31.9% 对 37.2%，P = 0.008）和中心性肥胖患病率（25.9% 对 35.4%，P = 0.0002）显著高于2007年（n = 45956）。总体人群中超重和1级或2级高血压患病率无显著变化，但2017年20 - 29岁参与者中1级高血压患病率显著更高（P = 0.002），70岁及以上参与者中2级高血压患病率显著更高（P = 0.046）。
与2007年相比，2017年在调整人口统计学混杂因素后，中国大陆成年人中高血压和肥胖患病率显著更高。需要更有针对性的干预措施和预防策略，以抵消因高血压和肥胖患病率上升导致的心血管疾病风险增加。
中华医学会临床研究基金（批准号15010010589）、国家自然科学基金（批准号82000753）以及中华医学会基金会和中华糖尿病学会（批准号07020470055）。
